[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100391477":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":16,"centralContacts":21,"locations":26,"responsibleParty":56,"collaborators":7,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":7,"enrollmentInfo":67,"targetDuration":7,"studyType":70,"phases":7,"briefSummary":71,"conditions":72,"keywords":76,"overallStatus":28,"whyStopped":7,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Centre Hospitalier Universitaire, Amiens","OTHER",null,[9,12],{"type":6,"name":10,"description":11,"armGroupLabels":7,"otherNames":7},"venous ultrasound","Venous ultrasound will be performed on patients once a week, every week from the day of admission in Amiens Hospital until the day of patient discharge",{"type":13,"name":14,"description":15,"armGroupLabels":7,"otherNames":7},"BIOLOGICAL","blood sample","blood sample for coagulation and hemostasis analysis will be withdrawn from artery catheter from the day of admission in Amiens Hospital until the day of patient discharge",[17],{"name":18,"affiliation":19,"role":20},"Michel Slama, Pr","CHU Amiens","PRINCIPAL_INVESTIGATOR",[22],{"name":18,"role":23,"phone":24,"phoneExt":7,"email":25},"CONTACT","(33)3 22 08 78 41","slama.michel@chu-amiens.fr",[27],{"facility":19,"status":28,"city":29,"state":7,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"RECRUITING","Amiens","80480","France","FR",{"type":34,"coordinates":35},"Point",[36,37],2.3,49.9,{"lat":37,"lon":36},[40,41,45,48,50,52,54],{"name":18,"role":23,"phone":24,"phoneExt":7,"email":25},{"name":42,"role":23,"phone":43,"phoneExt":7,"email":44},"Julien Maizel, Pr","(33)3 22 08 78 07","maizel.julien@chu-amiens.fr",{"name":46,"role":47,"phone":7,"phoneExt":7,"email":7},"Yoann Zerbib, MD","SUB_INVESTIGATOR",{"name":49,"role":47,"phone":7,"phoneExt":7,"email":7},"Simon Soudet, MD",{"name":51,"role":47,"phone":7,"phoneExt":7,"email":7},"Valery Salle, MD",{"name":53,"role":47,"phone":7,"phoneExt":7,"email":7},"Philippe Lanoix, Pr",{"name":55,"role":47,"phone":7,"phoneExt":7,"email":7},"Claire Andrejak, Pr",{"type":57,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100391477","thrombo-embolic-events-in-hospitalized-patients-with-covid-19-serious-acute-pneumopathy-100391477",false,"NCT04377490","Thrombo Embolic Events in Hospitalized Patients With Covid-19 Serious Acute Pneumopathy","THROMBCOVID2","Inclusion Criteria:\n\n* all patients hospitalized in Amiens Hospital with COVID-19 infection\n\nExclusion Criteria:\n\n* patients\\\u003C 18 years","ALL","18 Years",{"count":68,"type":69},100,"ESTIMATED","OBSERVATIONAL","The understanding of haemostasis and inflammation cross-talk has gained considerable knowledge during the past decade in the field of arterial and venous thrombosis. Complex and delicately balanced interaction between coagulation and inflammation involve all cellular and humoral components.\n\nElements of the coagulation system such as activated thrombin, fibrinogen or factor Xa may increase inflammation by promoting the production of proinflammatory cytokines, chemokines, growth factors and adhesion molecules that lead to a procoagulant state amplifying the pathological process. Recent evidence supports inflammation as a common pathogenic contributor to both arterial and venous thrombosis, giving rise to the concept of inflammation induced thrombosis.\n\nPatients with infection of COVID-19 and severe pneumoniae seem to have higher risk of thromboembolism. The purpose of this project is to analyze hemostasis and coagulation of every hospitalized patient with infection of COVID-19.\n\nBlood sample for coagulation and hemostasis analysis will be collected on every patient hospitalized in Amiens hospital for COVID-19 infection. Thrombin time, factors V and II, fibrin\u002Ffibrinogen degradation products, antithrombin will be assessed every week. Anticardiolipin, anti-beta2 glycoprotein I and anti-annexin A2 antibodies IgG and IgM at day of admission and at fourth week after admission will be assessed. SARS-CoV2 viral load and serodiagnosis will be performed at the same time. At the same time venous ultrasound to diagnose thrombosis will be performed.",[73,74,75],"COVID-19","Hemostasis","Coagulation",[73,10,74,77],"coagulation","2025-05-23",{"date":80,"type":81},"2025-05-29","ACTUAL",{"date":83,"type":81},"2020-05-04",{"date":85,"type":69},"2025-11",{"name":5,"class":6},1]